Clinical Trial

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

Study acronym: BUSEQ
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2020 (before its estimated November 2023 completion). Its status may not reflect the trial's current state.
Summary
Because the anti-leukemic activity of busulfan, this dug is largely used in graft conditioning but in elderly and/or cormobid patienth an excess of toxicity is observed. This study focus on the possibility of significanty reducing this toxicity by customizing the doses of busulfan to individual PK parameters.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-06-29; most recent amendment 2020-11-16.
Trial Details
NCT Number NCT04451200
Lead Sponsor Institut Paoli-Calmettes
Conditions Acute Leukemia, Mielodysplasic Syndrome, Myeloproliferative Neoplasm
Enrollment 82 participants
Start Date 2020-11
Primary Completion 2023-11 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2020-11-17